{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:22:52Z","timestamp":1755217372100,"version":"3.43.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Community Genet"],"DOI":"10.1007\/s12687-025-00770-x","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T03:57:07Z","timestamp":1739419027000},"page":"455-466","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Is Brazil following global trends in high-cost treatments? The case of Pompe Disease"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6291-0857","authenticated-orcid":false,"given":"Bruna","family":"Bento dos Santos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1930-4528","authenticated-orcid":false,"given":"Cec\u00edlia","family":"de Oliveira Carvalho Faria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7307-4594","authenticated-orcid":false,"given":"H\u00e9rica N\u00fabia Cardoso","family":"Cirilo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8140-6496","authenticated-orcid":false,"given":"Al\u00edcia Dorneles","family":"Dornelles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0289-4947","authenticated-orcid":false,"given":"Haliton Alves","family":"de Oliveira Junior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7933-6687","authenticated-orcid":false,"given":"Ida Vanessa D.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"key":"770_CR5","unstructured":"Anvisa - Brazilian Health Regulatory Agency (2022) Notification of Temporary Discontinuation: Alglucosidase alfa. Available at: https:\/\/sad.anvisa.gov.br\/MicroStrategy\/servlet\/mstrWeb. Accessed 18 Dec 2024"},{"key":"770_CR6","unstructured":"Anvisa - Brazilian Health Regulatory Agency (2023) Notification of Temporary Discontinuation: Avalglucosidase alfa. Available at: https:\/\/sad.anvisa.gov.br\/MicroStrategy\/servlet\/mstrWeb. Accessed 18 Dec 2024"},{"key":"770_CR4","unstructured":"Anvisa - Brazilian Health Regulatory Agency (2021) Sanitary register: Avalglucosidase alfa. Available at: https:\/\/consultas.anvisa.gov.br\/#\/medicamentos\/2034225?substancia=32068. Accessed 18 Dec 2024"},{"key":"770_CR1","unstructured":"Anvisa - Brazilian Health Regulatory Agency, & Drug Market Regulation Chamber (2024) Lists of drug prices. Available at: https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/medicamentos\/cmed\/precos. Accessed 18 Dec 2024"},{"key":"770_CR2","unstructured":"Anvisa - Brazilian Health Regulatory Agency (2007) Sanitary register: Alglucosidase alfa. Available at: https:\/\/consultas.anvisa.gov.br\/#\/medicamentos\/1323181?substancia=25925. Accessed 18 Dec 2024"},{"key":"770_CR3","unstructured":"Anvisa - Brazilian Health Regulatory Agency (2017) Resolution of the Collegiate Board 205, of December 28, 2017. Available at: https:\/\/bvsms.saude.gov.br\/bvs\/saudelegis\/anvisa\/2017\/rdc0205_28_12_2017.pdf. Accessed 18 Dec 2024"},{"key":"770_CR7","unstructured":"Brazil (1990) Law No. 8.080, of September 19, 1990. Available at: https:\/\/www.planalto.gov.br\/ccivil_03\/leis\/l8080.htm. Accessed 18 Dec 2024"},{"key":"770_CR8","unstructured":"Brazil (2010) From exceptionality to care lines: the Specialized Component of Pharmaceutical Assistance. Accessed 18 Dec 2024"},{"key":"770_CR9","unstructured":"Brazil (2014) Ordinance No. 199, of January 30, 2014. Available at: https:\/\/bvsms.saude.gov.br\/bvs\/saudelegis\/gm\/2014\/prt0199_30_01_2014.html. Accessed 18 Dec 2024"},{"key":"770_CR10","unstructured":"Brazil (2019) Alglucosidase alfa as enzyme replacement therapy for Pompe disease. Available at: https:\/\/www.gov.br\/conitec\/pt-br\/midias\/relatorios\/2019\/relatorio_alfaalglicosidase_pompe.pdf. Accessed 18 Dec 2024"},{"key":"770_CR11","unstructured":"Brazil (2020) Clinical Protocol and Therapeutic Guidelines for Pompe Disease. Available at: http:\/\/antigo-conitec.saude.gov.br\/images\/Relatorios\/2020\/Relatorio_de_Recomendacao_PCDT_Doenca_de_pompe_FINAL_529_2020.pdf. Accessed 18 Dec 2024"},{"key":"770_CR12","unstructured":"Brazil (2021) Alglucosidase alfa as enzyme replacement therapy for late-onset Pompe disease. Available at: https:\/\/www.gov.br\/conitec\/pt-br\/midias\/relatorios\/2021\/20210602_relatorio_617_alfa-alglicosidase_dpit_p24.pdf. Accessed 18 Dec 2024"},{"key":"770_CR19","unstructured":"Brazil (2023) Ordinance GM\/MS No. 2.261, of December 8, 2023. Available at: https:\/\/www.in.gov.br\/web\/dou\/-\/portaria-gm\/ms-n-2.261-de-8-de-dezembro-de-2023-529259361. Accessed 18 Dec 2024"},{"key":"770_CR16","unstructured":"Brazil (2022d) Ordinance GM\/MS No. 4.228, of December 6, 2022. Available at: https:\/\/bvsms.saude.gov.br\/bvs\/saudelegis\/gm\/2022\/prt4228_07_12_2022.html. Accessed 18 Dec 2024"},{"key":"770_CR20","unstructured":"Brazil (2024a) Contracts of the Department of Health Logistics - DLOG. Available at: https:\/\/www.gov.br\/saude\/pt-br\/acesso-a-informacao\/licitacoes-e-contratos\/contratos-dlog. Accessed 18 Dec 2024"},{"key":"770_CR21","unstructured":"Brazil (2024b) Requests for Health Technology Assessment. Available at: https:\/\/www.gov.br\/conitec\/pt-br\/assuntos\/avaliacao-de-tecnologias-em-saude\/tecnologias-demandadas. Accessed 18 Dec 2024"},{"key":"770_CR22","unstructured":"Brazil (2024c) Topic 1234 - Passive legitimacy of the Union and competence of the Federal Court in lawsuits concerning the supply of drugs registered with the National Health Surveillance Agency - ANVISA, but not standardized in the Unified Health System - SUS. Available at: https:\/\/portal.stf.jus.br\/jurisprudenciaRepercussao\/tema.asp?num=1234. Accessed 18 Dec 2024"},{"key":"770_CR18","unstructured":"Brazil (2022f) Extrajudicial report: DMPF-e No. 18\/2022. Available at: http:\/\/www.transparencia.mpf.mp.br\/conteudo\/diarios-e-boletins\/diario-eletronico-dmpf-e\/2022\/DMPF-EXTRAJUDICIAL-2022-01-27.pdf. Accessed 18 Dec 2024"},{"key":"770_CR15","unstructured":"Brazil (2022c) National List of Essential Medicines (RENAME) 2022. https:\/\/www.conass.org.br\/wp-content\/uploads\/2022\/01\/RENAME-2022.pdf. Available at: Accessed 18 Dec 2024"},{"key":"770_CR17","unstructured":"Brazil (2022e) Onasemnogene abeparvovec for the treatment of spinal muscular atrophy (SMA). Available at: https:\/\/www.gov.br\/conitec\/pt-br\/midias\/relatorios\/portaria\/2022\/20221207_relatorio_zolgensma_ame_tipo_i_793_2022.pdf. Accessed 18 Dec 2024"},{"key":"770_CR13","unstructured":"Brazil (2022a) The use of cost-effectiveness thresholds in health decisions: Recommendations from the National Commission for the Incorporation of Technologies in SUS. Available at: https:\/\/www.gov.br\/conitec\/pt-br\/midias\/pdf\/2022\/20221106_relatorio-uso-de-limiares-de-custo-efetividade-nas-decisoes-em-saude.pdf. Accessed 18 Dec 2024"},{"key":"770_CR14","unstructured":"Brazil (2022b) Alglucosidase alfa (Myozyme\u00ae) for the treatment of late-onset Pompe disease. Available at: https:\/\/www.gov.br\/conitec\/pt-br\/midias\/relatorios\/2022\/20220927_relatorio_769_alfaalglicosidase_final.pdf. Accessed 18 Dec 2024"},{"key":"770_CR24","unstructured":"CADTH - Canadian Agency for Drugs and Technologies in Health (2024b) Available at: https:\/\/www.cadth.ca\/avalglucosidase-alfa. Accessed 18 Dec 2024"},{"key":"770_CR23","unstructured":"CADTH - Canadian Agency for Drugs and Technologies in Health (2024a) Alglucosidase. Available at: https:\/\/www.cadth.ca\/alglucosidase. Accessed 18 Dec 2024"},{"key":"770_CR25","unstructured":"Chile, Ministry of Health (2017) Enfermedad de Pompe. Available at: https:\/\/docs.bvsalud.org\/biblioref\/2018\/04\/882714\/enfermedad-de-pompe-ok.pdf. Accessed 18 Dec 2024"},{"key":"770_CR26","unstructured":"Chile, Ministry of Health (2018) Enfermedad de Pompe. Available at: https:\/\/docs.bvsalud.org\/biblioref\/2019\/10\/1021880\/enfermedad_pompe.pdf. Accessed 18 Dec 2024"},{"issue":"8","key":"770_CR27","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.jval.2012.09.004","volume":"15","author":"A C\u00f4t\u00e9","year":"2012","unstructured":"C\u00f4t\u00e9 A, Keating B (2012) What is wrong with orphan drug policies? Value Health 15(8):1185\u20131191. https:\/\/doi.org\/10.1016\/j.jval.2012.09.004","journal-title":"Value Health"},{"issue":"3","key":"770_CR28","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/mus.22329","volume":"45","author":"EJ Cupler","year":"2012","unstructured":"Cupler EJ, Berger KI, Leshner RT, Wolfe GI, Han JJ, Barohn RJ, Kissel JT (2012) Consensus treatment recommendations for late-onset pompe disease. Muscle Nerve 45(3):319\u2013333. https:\/\/doi.org\/10.1002\/mus.22329","journal-title":"Muscle Nerve"},{"issue":"12","key":"770_CR29","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","volume":"20","author":"J Diaz-Manera","year":"2021","unstructured":"Diaz-Manera J, Kishnani PS, Kushlaf H, Ladha S, Mozaffar T, Straub V, Toscano A, van der Ploeg AT, Berger KI, Clemens PR, Chien YH, Day JW, Illarioshkin S, Roberts M, Attarian S, Borges JL, Bouhour F, Choi YC, Erdem-Ozdamar S, Zagnoli F (2021) Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset pompe disease (COMET): a phase 3, randomised, multicentre trial. Lancet Neurol 20(12):1012\u20131026. https:\/\/doi.org\/10.1016\/S1474-4422(21)00241-6","journal-title":"Lancet Neurol"},{"issue":"21","key":"770_CR31","doi-asserted-by":"publisher","first-page":"4828","DOI":"10.3390\/jcm10214828","volume":"10","author":"AD Dornelles","year":"2021","unstructured":"Dornelles AD, Junges APP, Pereira TV, Krug BC, Gon\u00e7alves CBT, Llerena JC, Kishnani PS, de Oliveira HA, Schwartz IVD (2021) A systematic review and meta-analysis of enzyme replacement therapy in late-onset pompe disease. J Clin Med 10(21):4828. https:\/\/doi.org\/10.3390\/jcm10214828","journal-title":"J Clin Med"},{"key":"770_CR30","doi-asserted-by":"publisher","unstructured":"Dornelles AD, Junges APP, Krug B, Gon\u00e7alves C, de Oliveira Junior HA, Schwartz IVD (2024) Efficacy and safety of enzyme replacement therapy with alglucosidase alfa for the treatment of patients with infantile-onset pompe disease: a systematic review and meta-analysis. Front Pediatr 12. https:\/\/doi.org\/10.3389\/fped.2024.1310317","DOI":"10.3389\/fped.2024.1310317"},{"key":"770_CR33","unstructured":"EMA - European Medicines Agency (2024b) Nexviadyme. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/nexviadyme. Accessed 18 Dec 2024"},{"key":"770_CR32","unstructured":"EMA - European Medicines Agency (2024a) Myozyme. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/myozyme#assessment-history. Accessed 18 Dec 2024"},{"key":"770_CR34","unstructured":"FDA - Food and Drug Administration (2013) Orphan Drug Act - Relevant Excerpts. Available at: https:\/\/www.fda.gov\/industry\/designating-orphan-product-drugs-and-biological-products\/orphan-drug-act-relevant-excerpts. Accessed 18 Dec 2024"},{"key":"770_CR35","unstructured":"FDA - Food and Drug Administration (2024a) Drug approval package: Myozyme (alglucosidase alfa). Available ate: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2006\/125141s000_MyozymeTOC.cfm. Accessed 18 Dec 2024"},{"key":"770_CR36","unstructured":"FDA - Food and Drug Administration (2024b) Drug approval package: Nexviazyme (avalglucosidase alfa). Available at: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trials-snapshot-nexviazyme. Accessed 18 Dec 2024"},{"issue":"10","key":"770_CR37","doi-asserted-by":"publisher","first-page":"e0140002","DOI":"10.1371\/journal.pone.0140002","volume":"10","author":"T Gammie","year":"2015","unstructured":"Gammie T, Lu CY, Babar ZU-D (2015) Access to orphan drugs: a comprehensive review of legislations, regulations and policies in 35 countries. PLoS ONE 10(10):e0140002. https:\/\/doi.org\/10.1371\/journal.pone.0140002","journal-title":"PLoS ONE"},{"key":"770_CR38","unstructured":"HAS - Haute Autorit\u00e9 de Sant\u00e9 (2024a) Myozyme (alpha-alglucosidase). Available at: https:\/\/www.has-sante.fr\/jcms\/pprd_2983670\/en\/myozyme-alpha-alglucosidase. Accessed 18 Dec 2024"},{"key":"770_CR39","unstructured":"HAS - Haute Autorit\u00e9 de Sant\u00e9 (2024b) Nexviadyme (avalglucosidase alfa). Available at: https:\/\/www.has-sante.fr\/jcms\/p_3374119\/en\/nexviadyme-avalglucosidase-alfa. Accessed 18 Dec 2024"},{"key":"770_CR40","unstructured":"HAS - Haute Autorit\u00e9 de Sant\u00e9 (2024c) Pombiliti (cipaglucosidase alfa). Available at: https:\/\/www.has-sante.fr\/jcms\/p_3456871\/en\/pombiliti-cipaglucosidase-alfa. Accessed 18 Dec 2024"},{"key":"770_CR41","doi-asserted-by":"publisher","unstructured":"Hasan SS, Lu CY, Babar ZU-D (2018) Access to high-cost medicines: an overview. Equitable Access to high-cost pharmaceuticals. Elsevier, pp 1\u201310. https:\/\/doi.org\/10.1016\/B978-0-12-811945-7.00001-4","DOI":"10.1016\/B978-0-12-811945-7.00001-4"},{"key":"770_CR42","unstructured":"IETSI - Instituto de Evaluaci\u00f3n de Tecnolog\u00edas en Salud e Investigaci\u00f3n (2019a) Dictamen N\u00b0 040-SDEPFyOTS-DETS-IETSI-2019. Available at: https:\/\/ietsi.essalud.gob.pe\/dictamenes\/dictamen-n-040-sdepfyots-dets-ietsi-2019\/. Accessed 18 Dec 2024"},{"key":"770_CR43","unstructured":"IETSI - Instituto de Evaluaci\u00f3n de Tecnolog\u00edas en Salud e Investigaci\u00f3n (2019b) Dictamen N\u00b0 019-SDEPFyOTS-DETS-IETSI-2019. Available at: https:\/\/ietsi.essalud.gob.pe\/dictamenes\/dictamen-n-019-sdepfyots-dets-ietsi-2019\/. Accessed 18 Dec 2024"},{"issue":"5","key":"770_CR44","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","volume":"8","author":"PS Kishnani","year":"2006","unstructured":"Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, Crowley JF, Downs S, Howell RR, Kravitz RM, Mackey J, Marsden D, Martins AM, Millington DS, Nicolino M, O\u2019Grady G, Patterson MC, Rapoport DM, Slonim A, Watson MS (2006) Pompe disease diagnosis and management guideline. Genet Med 8(5):267\u2013288. https:\/\/doi.org\/10.1097\/01.gim.0000218152.87434.f3","journal-title":"Genet Med"},{"issue":"1","key":"770_CR45","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1017\/S0266462310001297","volume":"27","author":"M Klemp","year":"2011","unstructured":"Klemp M, Fr\u00f8nsdal KB, Facey K (2011) What principles should govern the use of managed entry agreements? Int J Technol Assess Health Care 27(1):77\u201383. https:\/\/doi.org\/10.1017\/S0266462310001297","journal-title":"Int J Technol Assess Health Care"},{"issue":"2","key":"770_CR46","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1590\/0004-282X20150194","volume":"74","author":"JC Llerena Junior","year":"2015","unstructured":"Llerena Junior JC, Nascimento OJM, Oliveira ASB, Dourado Junior MET, Marrone CD, Siqueira HH, Sobreira CFR, Dias-Tosta E, Werneck LC (2015) Guidelines for the diagnosis, treatment and clinical monitoring of patients with juvenile and adult pompe disease. Arq Neuropsiquiatr 74(2):166\u2013176. https:\/\/doi.org\/10.1590\/0004-282X20150194","journal-title":"Arq Neuropsiquiatr"},{"key":"770_CR47","unstructured":"National Institute of Industrial Property (2024) Patent: BR 11 2014 022624 5 A2. Available at: https:\/\/busca.inpi.gov.br\/PePI\/. Accessed 18 Dec 2024"},{"key":"770_CR48","unstructured":"NHS England (2024) Cancer drugs fund. Available at: https:\/\/www.england.nhs.uk\/cancer\/cdf\/. Accessed 18 Dec 2024"},{"key":"770_CR50","unstructured":"NICE - National Institute for Health and Care Excellence (2023) Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease. Available at: https:\/\/www.nice.org.uk\/guidance\/ta912. Accessed 18 Dec 2024"},{"key":"770_CR49","unstructured":"NICE - National Institute for Health and Care Excellence (2022) Avalglucosidase alfa for treating Pompe disease. Available at: https:\/\/www.nice.org.uk\/guidance\/ta821. Accessed 18 Dec 2024"},{"key":"770_CR51","unstructured":"OECD - Organisation for Economic Co-operation and Development (2024) Performance-based managed entry agreements for new medicines. Available at: https:\/\/web-archive.oecd.org\/temp\/2023-04-20\/539425-pharma-managed-entry-agreements.htm. Accessed 18 Dec 2024"},{"key":"770_CR55","unstructured":"PBAC - Pharmaceutical Benefits Advisory Committee (2011) Alglucosidase - Public Summary Document, July 2011. Available at: https:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac-meetings\/psd\/2011-07\/pbac-psd-alglucosidase-july11. Accessed 18 Dec 2024"},{"key":"770_CR57","unstructured":"PBAC - Pharmaceutical Benefits Advisory Committee (2013) Alglucosidase - Public Summary Document, March 2013. Available at: https:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac-meetings\/psd\/2013-03\/alglucosidase. Accessed 18 Dec 2024"},{"key":"770_CR56","unstructured":"PBAC - Pharmaceutical Benefits Advisory Committee (2012) Alglucosidase alfa - Public Summary Document, November 2012. Available at: https:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac-meetings\/psd\/2012-11\/alglucosidase-alfa-rch. Accessed 18 Dec 2024"},{"key":"770_CR54","unstructured":"PBAC - Pharmaceutical Benefits Advisory Committee (2010) Alglucosidase alfa - Public Summary Document, November 2010. Available at: https:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac-meetings\/psd\/2010-11\/pbac-psd-alglucosidase-alfa-nov10. Accessed 18 Dec 2024"},{"key":"770_CR53","unstructured":"PBAC - Pharmaceutical Benefits Advisory Committee (2009) Alglucosidase - Public Summary Document, November 2009. Available at: https:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac-meetings\/psd\/2009-11\/pbac-psd-Alglucosidase-nov09. Accessed 18 Dec 2024"},{"key":"770_CR52","unstructured":"PBAC - Pharmaceutical Benefits Advisory Committee (2008) Alglucosidase - Public Summary Document, July 2008. Available at: https:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac-meetings\/psd\/2008-07\/pbac-psd-alglucosidase-july08. Accessed 18 Dec 2024"},{"key":"770_CR58","unstructured":"PBAC - Pharmaceutical Benefits Advisory Committee (2021) Recommendations made by the PBAC, November 2021. Available at: https:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac-meetings\/pbac-outcomes\/recommendations-made-by-the-pbac-november-2021. Accessed 18 Dec 2024"},{"key":"770_CR59","unstructured":"Sanofi (2023) Comunicado sobre a descontinua\u00e7\u00e3o tempor\u00e1ria de fabrica\u00e7\u00e3o\/importa\u00e7\u00e3o do medicamento LASIX\u00ae (furosemida) 10\u00a0mg\/mL solu\u00e7\u00e3o injet\u00e1vel. Available at: https:\/\/www.sanofi.com.br\/pt\/noticias\/informacoes-de-produtos\/2023-04-18-descontinuacao-nexviazyme. Accessed 18 Dec 2024"},{"issue":"12","key":"770_CR60","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S1474-4422(21)00331-8","volume":"20","author":"B Schoser","year":"2021","unstructured":"Schoser B, Roberts M, Byrne BJ, Sitaraman S, Jiang H, Lafor\u00eat P, Toscano A, Castelli J, D\u00edaz-Manera J, Goldman M, van der Ploeg AT, Bratkovic D, Kuchipudi S, Mozaffar T, Kishnani PS, Sebok A, Pestronk A, Dominovic-Kovacevic A, Khan A, Chien YH (2021) Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial. Lancet Neurol 20(12):1027\u20131037. https:\/\/doi.org\/10.1016\/S1474-4422(21)00331-8","journal-title":"Lancet Neurol"},{"key":"770_CR61","unstructured":"SMC - Scottish Medicines Consortium (2007) Alglucosidase alfa (Myozyme\u00ae). Available at: https:\/\/scottishmedicines.org.uk\/medicines-advice\/alglucosidase-alfa-myozyme-fullsubmission-35207\/. Accessed 18 Dec 2024"},{"key":"770_CR62","unstructured":"SMC - Scottish Medicines Consortium (2023a) Avalglucosidase alfa (Nexviadyme). Available at: https:\/\/scottishmedicines.org.uk\/medicines-advice\/avalglucosidase-alfa-nexviadyme-abb-smc2546\/. Accessed 18 Dec 2024"},{"key":"770_CR63","unstructured":"SMC - Scottish Medicines Consortium (2023b) Cipaglucosidase alfa (Pombiliti). Available at: https:\/\/scottishmedicines.org.uk\/medicines-advice\/cipaglucosidase-alfa-pombiliti-abb-smc2606\/. Accessed 18 Dec 2024"},{"issue":"Suppl 3","key":"770_CR64","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1590\/S1413-81232010000900019","volume":"15","author":"MV Souza","year":"2010","unstructured":"Souza MV, Krug BC, Picon PD, Schwartz IVD (2010) Medicamentos De alto custo para doen\u00e7as raras no Brasil: o exemplo das doen\u00e7as lisoss\u00f4micas. Cien Saude Colet 15(Suppl 3):3443\u20133454. https:\/\/doi.org\/10.1590\/S1413-81232010000900019","journal-title":"Cien Saude Colet"},{"issue":"12","key":"770_CR65","doi-asserted-by":"publisher","first-page":"e234611","DOI":"10.1001\/jamahealthforum.2023.4611","volume":"4","author":"F Trotta","year":"2023","unstructured":"Trotta F, Guerrizio MA, Di Filippo A, Cangini A (2023) Financial outcomes of managed entry agreements for pharmaceuticals in Italy. JAMA Health Forum 4(12):e234611. https:\/\/doi.org\/10.1001\/jamahealthforum.2023.4611","journal-title":"JAMA Health Forum"},{"issue":"9646","key":"770_CR66","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","volume":"372","author":"AT van der Ploeg","year":"2008","unstructured":"van der Ploeg AT, Reuser AJ (2008) Pompe\u2019s disease. Lancet 372(9646):1342\u20131353. https:\/\/doi.org\/10.1016\/S0140-6736(08)61555-X","journal-title":"Lancet"},{"issue":"4","key":"770_CR67","doi-asserted-by":"publisher","first-page":"119","DOI":"10.17566\/ciads.v8i4.559","volume":"8","author":"SH Vilvert","year":"2019","unstructured":"Vilvert SH, Buendgens FB, Campos Neto OH, de Oliveira J\u00fanior HA (2019) Perfil Das a\u00e7\u00f5es judiciais em assist\u00eancia \u00e0 sa\u00fade com bloqueio de verbas p\u00fablicas no Estado De Santa Catarina. Cad Ibero-Am Direito Sanit 8(4):119\u2013144. https:\/\/doi.org\/10.17566\/ciads.v8i4.559","journal-title":"Cad Ibero-Am Direito Sanit"}],"container-title":["Journal of Community Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12687-025-00770-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12687-025-00770-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12687-025-00770-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T13:04:28Z","timestamp":1754399068000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12687-025-00770-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":67,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["770"],"URL":"https:\/\/doi.org\/10.1007\/s12687-025-00770-x","relation":{},"ISSN":["1868-6001"],"issn-type":[{"type":"electronic","value":"1868-6001"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"assertion":[{"value":"16 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"B. B. S, C. O. C. F, H. N. C. C, A. D. D, H. A. O. J e I. V. D. S declare that they have no conflict of interest. This article does not contain any studies with human or animal subjects performed by any of the authors. This study has no funding.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}